Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Report 2026

The viral vector contract development and manufacturing organization (cdmo) market size has grown rapidly in recent years. It will grow from $1.47 billion in 2025 to $1.7 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to growing clinical pipeline of gene therapies, early outsourcing of viral vector production, expansion of academic research collaborations, limited in-house manufacturing capabilities of biotech firms, increasing regulatory approvals for viral vectors.

The viral vector contract development and manufacturing organization (cdmo) market size is expected to see rapid growth in the next few years. It will grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to rising commercialization of gene and cell therapies, increasing investments in dedicated viral vector facilities, growing demand for scalable manufacturing platforms, expansion of global cdmo partnerships, advances in high-yield vector production technologies. Major trends in the forecast period include expanding capacity for large-scale viral vector production, increasing adoption of single-use manufacturing technologies, growing demand for end-to-end cdmo services, rising focus on regulatory-compliant cGMP facilities, enhanced integration of advanced analytics in vector manufacturing.

The rising investment in gene therapy research is set to fuel expansion in the viral vector contract development and manufacturing organization (CDMO) market. Gene therapy research centers on developing techniques to modify or control genes in human cells, aiming to treat genetic disorders or fight diverse diseases. Funding for this field is increasing because of its promise to deliver lasting or one-time cures for genetic conditions that were once incurable, sparking keen interest from healthcare pioneers and investors alike. Viral vector CDMOs aid gene therapy efforts by providing specialized expertise and cutting-edge manufacturing capabilities to produce top-tier viral vectors, essential for safely and efficiently delivering therapeutic genes. For instance, in July 2025, the Office for Life Sciences - a UK government department - announced a commitment of up to $800 million (£600 million) to build one of the world's most advanced, secure, and AI-ready health data platforms. This initiative will merge genomic, diagnostic, and clinical data at a population scale, turning NHS and wider healthcare data into a global center for research trials and AI-driven investments. Thus, the surge in gene therapy research funding is propelling growth in the viral vector CDMO market.

Major players in the viral vector CDMO market are prioritizing innovative AAV manufacturing solutions to enable scalable, reliable production. These AAV solutions encompass specialized techniques and systems designed for the efficient creation of safe, potent adeno-associated virus vectors used in gene therapy. For example, in August 2025, ProBio - a U.S.-based CDMO - introduced cGMP AAV manufacturing services at its state-of-the-art 128,000 sq. ft. facility in Hopewell, New Jersey. This initiative addresses the surging need for premium viral vectors and underscores ProBio’s commitment to advancing cutting-edge gene therapies. The Hopewell site is specifically engineered to deliver end-to-end AAV manufacturing under stringent global regulatory and quality guidelines. ProBio now offers seamless, integrated services - including GMP plasmid DNA production, AAV vector manufacturing, and sterile fill/finish for final drug products - all from one U.S. site. This unified model improves oversight, minimizes transfer risks, and accelerates timelines throughout the drug development process.

In May 2023, Siegfried, a Switzerland-based life sciences firm, purchased a 95% stake in DINAMIQS for an undisclosed sum. Through this acquisition, Siegfried plans to expand DINAMIQS’ capabilities to commercial scale, establishing it as a top biotech CDMO for cell and gene therapies. The deal bolsters Siegfried’s footprint in the biologics field and promises significant mid- to long-term growth in a fast-growing market. DINAMIQS, based in Switzerland, offers full contract development and manufacturing services for viral vectors.

Major companies operating in the viral vector contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Genesail Biotech Co. Ltd., CEVEC Pharmaceuticals, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc.

North America was the largest region in the viral vector contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector contract development and manufacturing organization (cdmo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viral vector CDMO market by increasing the cost of imported bioreactors, filtration systems, single-use consumables, analytical instruments, and cold chain equipment used in upstream and downstream manufacturing. North America and Europe are most affected due to reliance on specialized imported bioprocessing equipment, while Asia-Pacific faces cost pressure on facility expansion projects. These tariffs are increasing capital expenditure and operational costs for CDMOs and their clients. However, they are also encouraging localized equipment sourcing, regional manufacturing ecosystem development, and long-term investments in domestic bioprocess infrastructure.

The viral vector contract development and manufacturing organization (cdmo) market research report is one of a series of new reports that provides viral vector contract development and manufacturing organization (cdmo) market statistics, including viral vector contract development and manufacturing organization (cdmo) industry global market size, regional shares, competitors with a viral vector contract development and manufacturing organization (cdmo) market share, detailed viral vector contract development and manufacturing organization (cdmo) market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector contract development and manufacturing organization (cdmo) industry. This viral vector contract development and manufacturing organization (cdmo) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A viral vector contract development and manufacturing organization (CDMO) is a specialized firm that concentrates on developing and producing viral vectors at scale for cutting-edge biological treatments. It delivers the essential technical expertise, facilities, and regulatory adherence required to handle the full viral vector production process.

Viral vector contract development and manufacturing organizations (CDMO) provide key services like process development, manufacturing, analytical testing, fill-finish, and more. Process development in pharmaceutical manufacturing entails designing and refining production processes to achieve efficient, scalable, and consistent results. Various vector types encompass adenoviral vectors, lentiviral vectors, adeno-associated viral vectors, retroviral vectors, and others, with workflows including upstream manufacturing and downstream manufacturing. Applications span gene therapy, vaccines, cell therapy, and beyond, serving end-users such as pharmaceutical and biotechnology companies, academic and research institutes, and others.

The viral vector contract development and manufacturing organization (CDMO) market consists of revenues earned by entities by providing services such as cell line development, preclinical material production, quality control testing, and supply chain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral vector contract development and manufacturing organization (CDMO) market also includes sales of helper plasmids, packaging cell lines, producer cell banks, and purified viral vector components. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.